Smith & Nephew releases new DURAFIBER™ Ag dressing to address bacterial contamination

   Smith & Nephew releases new DURAFIBER™ Ag dressing to address bacterial

PR Newswire

ST. PETERSBURG, Fla., Sept. 13, 2013

ST. PETERSBURG, Fla., Sept. 13, 2013 /PRNewswire/ --Smith & Nephew (LSE:SN,
NYSE:SNN), the global medical technology business, announces the US
introduction of DURAFIBER Ag antimicrobial gelling fiber dressing. This new
offering in the DURAFIBER portfolio combines the highly absorbent, gelling
fiber filler dressing with the benefits of silver (Ag). The addition of this
broad-spectrum antimicrobial provides clinicians with a different approach to
address bacterial contamination posed by medium to heavily exuding wounds.

"DURAFIBER Ag is strong when wet - a key attribute for ease of use for gelling
fiber dressings," says Robin Carlstein, Interim President North America
Advanced Wound Management. "US Clinicians will now have the effective exudate
management and anti-shrinkage properties of the DURAFIBER dressings with the
addition of a broad-spectrum antimicrobial. The DURAFIBER portfolio
facilitates clean, cost-effective, one-piece dressing removal continuing on
the Smith & Nephew commitment to deliver consistent clinical and economic
benefits for wound care."

For more information about DURAFIBER and DURAFIBER Ag, visit

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has around 11,000 employees and a presence in more than 90 countries.
Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member
of the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission under the
U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's
most recent annual report on Form 20-F, for a discussion of certain of these
Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations. 

^™ Trademark of Smith & Nephew. Certain marks registered US Patent and
Trademark Office.

SOURCE Smith & Nephew

Contact: Media, Beth Bentley, Smith & Nephew, 727-399-3779; Analyst/Investor,
Phil Cowdy, +44 (0) 20 7401 7646
Press spacebar to pause and continue. Press esc to stop.